Literature DB >> 6199966

Multiple immunoperoxidase markers in benign hyperplasia and adenocarcinoma of the prostate.

D W Ellis, S Leffers, J S Davies, A B Ng.   

Abstract

A series of 60 cases of prostatic adenocarcinoma and 34 cases of benign prostatic hyperplasia were examined quantitatively after immunoperoxidase staining for prostate-specific antigen (PSA), prostate-specific acid phosphatase (PSAP), carcino-embryonic antigen (CEA), epithelial membrane antigen (EMA), alpha fetoprotein (AFP), and human chorionic gonadotrophin (HCG). The tumors were graded I to IV according to the MDAH grading system recently proposed. Fifty-nine of the 60 tumors were positive for PSA and 58 were positive for PSAP. The one PSA and PSAP negative case was CEA negative and weakly EMA positive. Grade I to III tumors stained more tumor cells and more diffusely for PSA and PSAP than grade IV tumors. There was no significant difference in the intensity or extent of staining between grade I and grade II-III tumors for PSA and PSAP. A comparison of PSA and PSAP showed that PSA stained more intensely and more extensively than PSAP. Benign prostatic tissue and low-grade prostatic tumors did not stain for CEA but three of the 20 grade IV tumors and one of the 23 grade II-III tumors did. Staining for EMA was focal and showed no relation to tumor grade. Benign and malignant lesions failed to stain for AFP and HCG.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6199966     DOI: 10.1093/ajcp/81.3.279

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  12 in total

1.  Immunophenotypic Characterization of Benign and Malignant Prostatic Lesions.

Authors:  R Lakhtakia; R Bharadwaj; V K Kumar; P Mandal; S K Nema
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 2.  ACP Broadsheet No 146: August 1995. Macroscopic examination of prostatic specimens.

Authors:  P Harnden; M C Parkinson
Journal:  J Clin Pathol       Date:  1995-08       Impact factor: 3.411

3.  Cells in various benign and malignant conditions of the human prostate express different antigenic phenotypes.

Authors:  O I Turhan; N E Aydin; O Sariyüce; S Ozkan
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

4.  Variation of prostate-specific antigen expression in different tumour growth patterns present in prostatectomy specimens.

Authors:  M P Gallee; E Visser-de Jong; J A van der Korput; T H van der Kwast; F J ten Kate; F H Schroeder; J Trapman
Journal:  Urol Res       Date:  1990

5.  Effects of sex steroids on cell growth and C-myc oncogene expression in LN-CaP and DU-145 prostatic carcinoma cell lines.

Authors:  F K Asadi; R Sharifi
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

6.  Total protein and acid phosphatase concentrations in prostatic fluid from patients with BPH compared to carcinoma.

Authors:  E D Kim; N D Smith; J T Grayhack
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

7.  Prostate cancer markers: An update.

Authors:  Srinivas Pentyala; Terry Whyard; Sahana Pentyala; John Muller; John Pfail; Sunjit Parmar; Carlos G Helguero; Sardar Khan
Journal:  Biomed Rep       Date:  2016-01-29

8.  Phenotypic relationships of prostatic intraepithelial neoplasia to invasive prostatic carcinoma.

Authors:  R B Nagle; M K Brawer; J Kittelson; V Clark
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

9.  Immunohistochemical demonstration of prostate-specific antigen in metastases with the use of monoclonal antibody F5.

Authors:  L D Papsidero; G A Croghan; J Asirwatham; J Gaeta; P Abenoza; L Englander; L Valenzuela
Journal:  Am J Pathol       Date:  1985-12       Impact factor: 4.307

10.  Relationship between histologic grading and serum prostate specific antigen in prostatic carcinoma.

Authors:  M Lekili; M Zengin; H Postaci; A R Ayder
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.